Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Pharma Sale Remains Long-Term Option; CFO Wenning To Become CEO

Executive Summary

Bayer AG is leaving open the possibility of a sale of its pharmaceutical division over the long-term, while emphasizing that it remains a "core" business for now.

You may also be interested in...



Bayer Finds Partial Pharma Partner In Aventis Blood Products Joint Venture

Bayer/Aventis Behring's blood products joint venture would partly accomplish Bayer's goal of finding a strategic partner for its pharmaceutical business

Bayer Finds Partial Pharma Partner In Aventis Blood Products Joint Venture

Bayer/Aventis Behring's blood products joint venture would partly accomplish Bayer's goal of finding a strategic partner for its pharmaceutical business

Bayer Seeking Smaller Pharma Partner; Will Retain Majority Share In Deal

Bayer is in discussions with smaller specialty pharmaceutical companies over potential partnerships as it looks to build up its drug business

Related Content

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel